secondary progressive multiple sclerosis

Showing 1 - 25 of 41

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Secondary Progressive Multiple Sclerosis Trial in Germany (BAF312, Baseline disease modifying therapies (DMTs))

Active, not recruiting
  • Secondary Progressive Multiple Sclerosis
  • BAF312
  • Baseline disease modifying therapies (DMTs)
  • Mittweida, Sachsen, Germany
  • +9 more
Aug 9, 2022

Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in Australia, Canada, United States

Active, not recruiting
  • Primary Progressive Multiple Sclerosis
  • Secondary Progressive Multiple Sclerosis
  • ATA188
  • Placebo
  • La Jolla, California
  • +33 more
Jul 21, 2022

Secondary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis Trial in Salt Lake City

Recruiting
  • Secondary Progressive Multiple Sclerosis
  • +2 more
  • Ferumoxytol infusion
  • +2 more
  • Salt Lake City, Utah
    University of Utah Health Imaging and Neurosciences Center
Jun 22, 2022

Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis Trial in Los Angeles (Metformin 500 Mg Oral

Recruiting
  • Secondary Progressive Multiple Sclerosis
  • Primary Progressive Multiple Sclerosis
  • Metformin 500 Mg Oral Tablet, up to 4 tablets a day
  • Placebo oral tablet identical to metformin, up to 4 tablets a day
  • Los Angeles, California
    University of California, Los Angeles
May 2, 2022

Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis Trial

Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • +2 more
  • Glostrup, Copenhagen, Denmark
  • +11 more
May 3, 2022

Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in Birmingham, Saint Louis (Glycemic

Not yet recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Secondary Progressive Multiple Sclerosis
  • Glycemic load
  • +2 more
  • Birmingham, Alabama
  • +1 more
Apr 6, 2022

Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis Trial

Active, not recruiting
  • Secondary Progressive Multiple Sclerosis
  • +2 more
  • Minneapolis, Minnesota
  • +2 more
Mar 29, 2022

Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in Caen (Cognitive rehabilitation,

Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Secondary Progressive Multiple Sclerosis
  • Cognitive rehabilitation
  • Standard Psychological care
  • Caen, Calvados, France
    University Hospital of Caen
Mar 8, 2022

Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial

Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • +2 more
  • Ixazomib (NINLARO®) capsules / Matching placebo capsules
  • London, Greater London, United Kingdom
    Royal London Hospital, Barts Health NHS Foundation Trust
Feb 17, 2022

Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Multiple Sclerosis Trial (Intranasal Foralumab

Withdrawn
  • Primary Progressive Multiple Sclerosis
  • +2 more
  • Intranasal Foralumab Solution
  • Placebo
  • (no location specified)
Feb 14, 2022

Measuring Active Microglia in Progressive Multiple Sclerosis

Completed
  • Secondary Progressive Multiple Sclerosis
  • [C11]PK-1195 PET scan
  • New York, New York
    Weill Cornell Medical College
Jan 14, 2022

Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Relapsing Multiple Sclerosis Trial in Boston

Recruiting
  • Primary Progressive Multiple Sclerosis
  • +3 more
  • Boston, Massachusetts
    Brigham and Women's Hospital
Jul 20, 2021

Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis Trial in Dublin (Fampridine, Placebo)

Completed
  • Secondary Progressive Multiple Sclerosis
  • Primary Progressive Multiple Sclerosis
  • Dublin, Dublin 4, Ireland
  • +1 more
Jul 8, 2021

Patient Research Cohort: Rapidly Evolving Multiple Sclerosis

Completed
  • Relapsing-remitting Multiple Sclerosis
  • Secondary Progressive Multiple Sclerosis
    • London, United Kingdom
      Imperial College NHS Trust
    Feb 11, 2021

    Phase III Trial With BAF312 in Secondary Progressive Multiple

    Completed
    • Secondary Progressive Multiple Sclerosis
    • Blood Draw
    • CSF collection by lumbar puncture (Optional)
    • Berkeley, California
    • +12 more
    Nov 5, 2020

    Secondary Progressive Multiple Sclerosis Trial in Nottingham (Acceptance Based Telephone Support (ABS+UC))

    Completed
    • Secondary Progressive Multiple Sclerosis
    • Acceptance Based Telephone Support (ABS+UC)
    • Nottingham, Nottinghamshire, United Kingdom
      Queens Medical Centre, Nottingham
    Sep 24, 2020

    Secondary Progressive Multiple Sclerosis Trial in London (Simvastatin)

    Unknown status
    • Secondary Progressive Multiple Sclerosis
    • London, United Kingdom
      Department of Neuroinflammation, UCL Institute of Neurology
    Mar 27, 2020

    Secondary Progressive Multiple Sclerosis Trial in United Kingdom (Amiloride, Riluzole, Fluoxetine)

    Completed
    • Secondary Progressive Multiple Sclerosis
    • Edinburgh, United Kingdom
    • +12 more
    Mar 25, 2020

    Secondary Progressive Multiple Sclerosis Trial in Baltimore (Active cycling, Passive cycling)

    Completed
    • Secondary Progressive Multiple Sclerosis
    • Active cycling
    • Passive cycling
    • Baltimore, Maryland
      Johns Hopkins / Kennedy Krieger Institute
    Mar 18, 2020

    Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in Barcelona (XCEL-MC-ALPHA, Placebo)

    Completed
    • Relapsing-Remitting Multiple Sclerosis
    • Secondary Progressive Multiple Sclerosis
    • Barcelona, Spain
      Hospital Vall Hebron
    Jan 15, 2020

    Secondary Progressive Multiple Sclerosis Trial in Chalfont St. Peter, Hammersmith, Brighton (Simvastatin, Placebo)

    Completed
    • Secondary Progressive Multiple Sclerosis
    • Chalfont St. Peter, Buckinghamshire, United Kingdom
    • +2 more
    Nov 21, 2019

    Secondary Progressive Multiple Sclerosis Trial in Ann Arbor (SoluMedrol, Extracorporeal Photopheresis)

    Terminated
    • Secondary Progressive Multiple Sclerosis
    • Ann Arbor, Michigan
      University of Michigan Health Systems
    Aug 8, 2019

    Secondary Progressive Multiple Sclerosis Trial in Isfahan (Rituximab, Glatiramer Acetate)

    Completed
    • Secondary Progressive Multiple Sclerosis
    • Isfahan, Iran, Islamic Republic of
      Kashani Hospital
    May 22, 2019

    Multiple Sclerosis, Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in Portland (Alpha Lipoic

    Completed
    • Multiple Sclerosis
    • +3 more
    • Alpha Lipoic Acid
    • Portland, Oregon
      Oregon Health & Science University
    Mar 20, 2019

    Mitochondrial Dysfunction and Disease Progression

    Completed
    • Clinically Isolated Syndrome
    • +3 more
      • New York, New York
        Icahn School of Medicine
      Feb 19, 2019